GMABGenmabRunning, no new patients
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma
Follicular Lymphoma (FL)
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 549 (final count)
- Started
- Sep 20, 2022
- Main results expected
- Dec 2029
- Fully finished
- Dec 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Percentage of Participants Achieving Best Overall Response (BOR)
Measured over: Up to approximately 2 years and 3 months
Progression-Free Survival (PFS)
Measured over: Up to approximately 2 years and 3 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05409066 · record last updated 2026-07-08 · checked 2026-11-09 15:47 UTC